Michael Tepedino

542 total citations
8 papers, 110 citations indexed

About

Michael Tepedino is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Pharmacology. According to data from OpenAlex, Michael Tepedino has authored 8 papers receiving a total of 110 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Ophthalmology, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Pharmacology. Recurrent topics in Michael Tepedino's work include Glaucoma and retinal disorders (5 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Ocular Infections and Treatments (2 papers). Michael Tepedino is often cited by papers focused on Glaucoma and retinal disorders (5 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Ocular Infections and Treatments (2 papers). Michael Tepedino collaborates with scholars based in United States, Switzerland and United Kingdom. Michael Tepedino's co-authors include Wolfgang Haas, Timothy W. Morris, Dale W. Usner, Timothy L. Comstock, Michael R. Paterno, Peter R Bernstein, Scott M. Whitcup, Rhett M. Schiffman, Richard W. Yee and Harold G. Jensen and has published in prestigious journals such as Current Medical Research and Opinion, Journal of Glaucoma and Ophthalmology Glaucoma.

In The Last Decade

Michael Tepedino

7 papers receiving 95 citations

Peers

Michael Tepedino

OPHTH

PHARM

MM

PHEOH

CB

G Grise France

Alison Cavalier France

Andrew Pastewski United States

Brian Tibbs United States

Kara Brady Australia

Seymour Waner South Africa

Laura Cascarano Italy

Gerard Gawrys United States

Roberto Giurazza Italy

Yaneicy Gonzalez‐Rojas United States

G Grise France

Michael Tepedino

3 ×0.0

OPHTH

34 ×0.7

PHARM

23 ×1.0

MM

4 ×0.2

PHEOH

7 ×0.5

CB

Citations per year, relative to Michael Tepedino Michael Tepedino (= 1×) peers G Grise

Countries citing papers authored by Michael Tepedino

Since Specialization

Citations

This map shows the geographic impact of Michael Tepedino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tepedino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tepedino more than expected).

Fields of papers citing papers by Michael Tepedino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tepedino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tepedino. The network helps show where Michael Tepedino may publish in the future.

Co-authorship network of co-authors of Michael Tepedino

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Tepedino. A scholar is included among the top collaborators of Michael Tepedino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Tepedino. Michael Tepedino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Wirta, David, Shérif M. El-Harazi, Michael Tepedino, & Jason Bacharach. (2025). Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology Glaucoma. 8(4). 384–392.

2.

Panarelli, Joseph F., Michael Tepedino, Noriko Odani‐Kawabata, et al.. (2023). Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study. Journal of Glaucoma. 32(12). 999–1005. 6 indexed citations

3.

Chen, Michelle Y., Kenneth Sall, Michael Tepedino, et al.. (2018). Patient-reported Outcomes of Bimatoprost Ocular Ring in an Open-label Extension Study in Patients with Open-angle Glaucoma or Ocular Hypertension. 59(9). 1231–1231. 1 indexed citations

4.

Schwab, Dietmar, Agnès Portron, Sabine Fuerst‐Recktenwald, et al.. (2017). Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study. BMJ Open Ophthalmology. 1(1). e000063–e000063. 8 indexed citations

5.

Sall, Kenneth, Shamik Bafna, Joseph Gira, et al.. (2017). Results of A Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP (travoprost insert) Compared to Timolol Drops for the Treatment of Patients with Open-Angle Glaucoma or Ocular Hypertension. 58(8). 2111–2111. 1 indexed citations

6.

Sall, Kenneth, James H. Peace, Douglas G. Day, et al.. (2014). Initial Clinical Evaluation of Safety, Tolerability and Pharmacodynamics of the Locally-Acting ROCK Inhibitor AMA0076. 55(13). 565–565. 5 indexed citations

7.

Tepedino, Michael, Dale W. Usner, Timothy W. Morris, et al.. (2009). Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Current Medical Research and Opinion. 25(5). 1159–1169. 64 indexed citations

8.

Yee, Richard W., Michael Tepedino, Peter R Bernstein, et al.. (2005). A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis. Current Medical Research and Opinion. 21(3). 425–431. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact